| Dr Rael David Sundy, MD | |
|
1035 Bellevue Ave, Suite 500, Saint Louis, MO 63117-1854 | |
| (314) 925-4744 | |
| (314) 925-4764 |
| Full Name | Dr Rael David Sundy |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 1035 Bellevue Ave, Saint Louis, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528015666 | NPI | - | NPPES |
| 1164534219 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 2004028846 (Missouri) | Primary |
| Entity Name | Ssm Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700966207 PECOS PAC ID: 6608776299 Enrollment ID: O20040729001034 |
News Archive
EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept's novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
CryoLife, Inc., a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.
Today we release the important update to our most ‘in demand' clinical guideline, on the Management of Gout. Gout is the most searched for term on our website and it's is a particularly painful form of arthritis which is becoming more common, yet continues to be poorly managed.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rael David Sundy, MD 1035 Bellevue Ave, Suite 500, Saint Louis, MO 63117-1854 Ph: (314) 925-4744 | Dr Rael David Sundy, MD 1035 Bellevue Ave, Suite 500, Saint Louis, MO 63117-1854 Ph: (314) 925-4744 |
News Archive
EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept's novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
CryoLife, Inc., a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.
Today we release the important update to our most ‘in demand' clinical guideline, on the Management of Gout. Gout is the most searched for term on our website and it's is a particularly painful form of arthritis which is becoming more common, yet continues to be poorly managed.
› Verified 9 days ago
Dr. Isik Turker, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4921 Parkview Pl, Div Im Cardiology, Ste 8b, Saint Louis, MO 63110 Phone: 314-362-1291 Fax: 314-362-4278 | |
Conor Mccartney, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 915 N Grand Blvd, Saint Louis, MO 63106 Phone: 314-652-4100 | |
Dr. Faris Adam Bakeer, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110 Phone: 314-362-1700 Fax: 314-362-9878 | |
Rehan Rais, M.D. M.B.,B.S. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 660 S Euclid Ave, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Nathan Farkas, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-1930 | |
Dr. Nicole Foley, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Soumojit Ghosh, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3660 Vista Ave, Saint Louis, MO 63110 Phone: 314-977-6100 Fax: 314-977-6164 |